Skip to main content
. 2022 Dec 13;13(3):598–615. doi: 10.1158/2159-8290.CD-22-0968

Figure 4.

Figure 4. NVL-520 inhibits ROS1-driven tumor xenografts. A–E, For each model, the change in tumor volume over time (left, plotted as mean ± SEM, with horizontal gray lines denoting mean starting tumor volume of the vehicle group) and a waterfall plot showing tumor volume changes from day 0 to the final timepoint shown (right) are provided. Average tumor volume changes are provided underneath the waterfall plots. For A and B, data are shown up to days 20 and 28, respectively; longer treatments are provided in Supplementary Fig. S13C and S13D. MGH9018-1 was confirmed to be crizotinib-resistant (C). *For 75 mg/kg repotrectinib, day 10 is the last reported data point due to lack of tolerability and loss of animals after day 10 (D). Each group contained 4–8 mice. All treatments were administered orally twice per day (b.i.d.). PDX = patient-derived xenograft; CDX = cell line–derived xenograft.

NVL-520 inhibits ROS1-driven tumor xenografts. A–E, For each model, the change in tumor volume over time (left, plotted as mean ± SEM, with horizontal gray lines denoting mean starting tumor volume of the vehicle group) and a waterfall plot showing tumor volume changes from day 0 to the final time point shown (right) are provided. Average tumor volume changes are provided underneath the waterfall plots. For A and B, data are shown up to days 20 and 28, respectively; longer treatments are provided in Supplementary Fig. S13C and S13D. MGH9018-1 was confirmed to be crizotinib-resistant (C). *For 75 mg/kg repotrectinib, day 10 is the last reported datapoint due to lack of tolerability and loss of animals after day 10 (D). Each group contained 4 to 8 mice. All treatments were administered orally b.i.d unless otherwise indicated. CDX, cell line–derived xenograft; q.d., once daily.